Gland Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	61,128	56,165	56,647	36,246	44,007	34,629
Revenue Growth (YoY)	6.70%	-0.85%	56.28%	-17.64%	27.08%	31.51%
Cost of Revenue	25,146	24,621	25,539	18,595	22,494	16,097
Gross Profit	35,982	31,544	31,108	17,651	21,513	18,532
Selling, General & Admin	16,011	14,120	12,668	4,047	3,397	3,122
Other Operating Expenses	5,474	4,878	5,065	3,271	3,009	2,385
Operating Expenses	25,638	22,822	21,393	8,807	7,513	6,498
Operating Income	10,344	8,721	9,715	8,844	14,000	12,034
Interest Expense	-260.98	-373.99	-217.9	-62.87	-34.02	-29.11
Interest & Investment Income	2,043	2,043	1,506	1,794	1,386	859.49
Currency Exchange Gain (Loss)	2.63	2.63	106.05	571.45	792.05	405.26
Other Non Operating Income (Expenses)	555.86	203.03	179.46	-1.07	-2.85	77.77
EBT Excluding Unusual Items	12,684	10,596	11,288	11,146	16,142	13,348
Gain (Loss) on Sale of Investments	12.27	12.27	3.48	28.48	44.89	-
Gain (Loss) on Sale of Assets	0.32	0.32	2.49	-0.81	-1.78	0.24
Asset Writedown	18.24	18.24	-	-63.32	-	-
Other Unusual Items	-243.46	-	-	-564.61	-	-
Pretax Income	12,471	10,627	11,325	10,546	16,186	13,348
Income Tax Expense	3,999	3,641	3,601	2,735	4,069	3,378
Net Income	8,472	6,985	7,725	7,810	12,117	9,970
Net Income to Common	8,472	6,985	7,725	7,810	12,117	9,970
Net Income Growth	20.27%	-9.57%	-1.10%	-35.54%	21.54%	29.00%
Shares Outstanding (Basic)	165	165	165	165	164	158
Shares Outstanding (Diluted)	165	165	165	165	165	158
Shares Change (YoY)	0.02%	0.01%	0.03%	0.09%	3.96%	2.15%
EPS (Basic)	51.42	42.40	46.90	47.44	73.81	63.07
EPS (Diluted)	51.42	42.40	46.89	47.43	73.64	62.99
EPS Growth	20.25%	-9.58%	-1.14%	-35.59%	16.91%	26.29%
Free Cash Flow	-	5,302	6,069	1,430	2,794	3,762
Free Cash Flow Per Share	-	32.18	36.84	8.69	16.98	23.77
Dividend Per Share	18.000	18.000	20.000	-	-	-
Dividend Growth	-	-10.00%	-	-	-	-
Gross Margin	58.86%	56.16%	54.92%	48.70%	48.88%	53.52%
Operating Margin	16.92%	15.53%	17.15%	24.40%	31.81%	34.75%
Profit Margin	13.86%	12.44%	13.64%	21.55%	27.53%	28.79%
Free Cash Flow Margin	-	9.44%	10.71%	3.95%	6.35%	10.86%
EBITDA	14,191	12,314	12,968	10,310	15,102	13,020
EBITDA Margin	23.21%	21.93%	22.89%	28.44%	34.32%	37.60%
D&A For EBITDA	3,847	3,593	3,253	1,466	1,101	985.75
EBIT	10,344	8,721	9,715	8,844	14,000	12,034
EBIT Margin	16.92%	15.53%	17.15%	24.40%	31.81%	34.75%
Effective Tax Rate	32.07%	34.27%	31.79%	25.94%	25.14%	25.31%
Revenue as Reported	63,617	58,301	58,350	38,651	46,246	35,977

Source: S&P Global Market Intelligence. Standard template. Financial Sources.